Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation
Neurogastroenterology & Motility · 2025
DOI: 10.1111/nmo.70012 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, 2025. Verfasst von Stefan Roos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Sciences, Uppsala BioCenter, Swedish University of Agricultural Sciences, Uppsala, Sweden. Hauptthemen laut MEDLINE: Constipation, Probiotics, Gastrointestinal Motility, Lactobacillus gasseri. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioGaia AB, Kungsbroplan.
Abstract (Originalsprache)
Background
Chronic constipation is a prevalent, burdensome gastrointestinal disorder whose etiology and pathophysiology remain poorly understood. Differences in the composition of the intestinal microbiota have been shown between constipated patients and healthy people. Data indicate that these microbial differences contribute to the disorder.
Methods
Preclinical studies in mice examined the effects of Lactobacillus gasseri on intestinal motility ex vivo, the reversal of motility inhibition by μ‐opioid receptor agonists ex vivo and in vivo in mice, and the effects on capsaicin‐stimulated transient receptor potential vanilloid 1 (TRPV1) in Jurkat cells. Thereafter, a clinical study of 40 women with functional constipation was conducted to investigate the effects of Lactobacillus gasseri with a randomized parallel design. After 14 days of baseline recording, treatment with Lactobacillus gasseri or placebo was given over 28 days, with 14 days of follow‐up. Outcomes with complete spontaneous bowel movements (CSBM), spontaneous bowel movements, emptying frequency, abdominal pain, time spent for defecation, Bristol stool form scale, use of rescue laxatives, and impact on sex life were investigated. Key Results In preclinical studies, Lactobacillus gasseri increased intestinal motility in an ex vivo model, reversed the motility inhibition caused by μ‐opioid receptor agonist ex vivo and in vivo in mice, and counteracted capsaicin‐stimulated activity of TRPV1 in Jurkat cells. In the clinical trial, Lactobacillus gasseri showed a significant reduction in abdominal pain, along with a correlation and tendency for an increased number of CSBM. Few adverse events were encountered. Conclusions and Inferences Treatment with Lactobacillus gasseri can alleviate pain sensations in functional constipation, possibly with an improved bowel‐emptying function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Sciences, Uppsala BioCenter, Swedish University of Agricultural Sciences, Uppsala, Sweden.
- BioGaia AB, Stockholm, Sweden.
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- Brain-Body Institute, McMaster University, Hamilton, Ontario, Canada.
- Department of Psychiatry, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Per M Hellström
Förderung
- BioGaia AB, Kungsbroplan
Zitieren
APA
Roos, S., Dahlgren, A. L., Mao, Y. K., Pallin, A., Stanisz, A. M., Forsythe, P., Kunze, W., & Hellström, P. M. (2025). Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70012
Vancouver
Roos S, Dahlgren AL, Mao YK, Pallin A, Stanisz AM, Forsythe P, et al. Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation. Neurogastroenterology & Motility. 2025. doi:10.1111/nmo.70012
BibTeX
@article{Roos2025,
author = {Roos, Stefan and Dahlgren, Atti-La and Mao, Yu-Kang and Pallin, Anton and Stanisz, Andrew M and Forsythe, Paul and Kunze, Wolfgang and Hellström, Per M},
title = {Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation},
journal = {Neurogastroenterology & Motility},
year = {2025},
doi = {10.1111/nmo.70012}
}
EUVIMED